Rational Pharmacotherapy of Respiratory Diseases in the COVID-19 Pandemic

Abstract

The purpose of this article is to draw attention to the treatment of respiratory diseases in the COVID-19 pandemic. In addition, we want to address the issue of vaccination, to pay attention to the incidence of disease among children. The design of this study was longitudinal. For this purpose, we use articles and studies from English-language sources, such as UpToDate, as well as peer-reviewed scientific articles from medical journals and the results of surveys of outpatient medical practitioners. There were no particular changes in the pharmacotherapy of respiratory diseases during the COVID-19 pandemic. Changes occurred in the recommendations for aerosol delivery of the drug, and it was recommended that the use of targeted therapy and the use of antileukotriene drugs for bronchial asthma with positive COVID be delayed until recovery. Covid is changing the doctor-patient communication system today, giving rise to telemedicine. He reminds us of the importance of vaccination in pandemics if it is possible, and it is already possible, and of the importance of population immunity. And also, we should not forget about the therapy of other diseases and consider the conditions of a pandemic when making treatment decisions.